Video
Author(s):
Key opinion leaders take time to review how immune checkpoint inhibitors have transformed outcomes in rectal cancer and non-cutaneous squamous cell cancers and consider how to better structure clinical trial endpoints in CSCC.
Long-Term Data for Up-Front Combinations Reaffirm Treatment Options in CLL
Community Oncologists on the Importance of Self-Reliance and Collegial Trust as Women in Medicine
New Case Study Highlights Community Oncology Practices as Preferred Site of Service Over Hospitals and Academic Centers
Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers
New Data With RP1 Plus Nivolumab in PD-1–Refractory Melanoma Build on Positive Findings
Neoadjuvant Nivolumab/Ipilimumab New Standard of Care for Stage III Melanoma
Lurbinectedin Plus Irinotecan Is Safe, Prolongs Responses in High-Risk, Pretreated SCLC
Axi-Cel Shows Safety, Clinical Activity in R/R Primary and Secondary CNS Lymphomas
Amphiphile Lymph Node–Targeted Vaccine Is Safe and Bolsters T-Cell Responses in MRD+ PDAC and CRC
JNJ-6420 Elicits Responses in mCRPC, But Safety Concerns Arise